Key AI trends in Drug Discovery

2023 was the year of AI. It would be difficult to finish your day without seeing or hearing at least 5 updates about developments related to AI, ChatGPT or language models.

The year was marked by significant strides and transformative collaborations for AI in drug discovery. While there was tough criticism of the hype as the first AI designed fell short in the clinic, the overall sentiment remains optimistic as the deal making continues.

1.     Generative AI for Antibody and Protein engineering was in the spotlight

There was a surge of big pharma partnerships and investments in AI-driven antibody and protein engineering, as the field caught up with similar advancements in AI for small molecule discovery.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for